TERM ID="NYU_TERM_1" STRING="Cancer cells" FREQUENCY=1 START=735 END=747 LEMMA="CANCER CELL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_2" STRING="T-cell immunity" FREQUENCY=1 START=1012 END=1027 LEMMA="T-CELL IMMUNITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_3" STRING="adaptive T-cell response" FREQUENCY=1 START=1065 END=1089 LEMMA="ADAPTIVE T-CELL RESPONSE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_4" STRING="anti-tumor" FREQUENCY=1 START=1053 END=1063 LEMMA="ANTI-TUMOR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_5" STRING="anti-tumor antibodies" FREQUENCY=1 START=325 END=346 LEMMA="ANTI-TUMOR ANTIBODY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_6" STRING="antibody treatment" FREQUENCY=1 START=579 END=597 LEMMA="ANTIBODY TREATMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_7" STRING="cancer development" FREQUENCY=1 START=1404 END=1422 LEMMA="CANCER DEVELOPMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_8" STRING="cancer immunotherapy" FREQUENCY=3 START=36 END=56 LEMMA="CANCER IMMUNOTHERAPY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_9" STRING="cancer immunotherapy" FREQUENCY=3 START=92 END=112 LEMMA="CANCER IMMUNOTHERAPY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_10" STRING="cancer immunotherapy" FREQUENCY=3 START=1623 END=1643 LEMMA="CANCER IMMUNOTHERAPY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_11" STRING="cancer patients" FREQUENCY=1 START=718 END=733 LEMMA="CANCER PATIENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_12" STRING="cellular effects" FREQUENCY=1 START=559 END=575 LEMMA="CELLULAR EFFECT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_13" STRING="cellular effects of antibody treatment" FREQUENCY=1 START=559 END=597 LEMMA="ANTIBODY TREATMENT CELLULAR EFFECT" LEMMA_FREQUENCY=1 HEAD_TERM="cellular effects" HEAD_LEMMA="CELLULAR EFFECT"
TERM ID="NYU_TERM_14" STRING="clinical cancer care" FREQUENCY=1 START=286 END=306 LEMMA="CLINICAL CANCER CARE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_15" STRING="clinical trials" FREQUENCY=1 START=244 END=259 LEMMA="CLINICAL TRIAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_16" STRING="combinatorial therapeutics" FREQUENCY=1 START=635 END=661 LEMMA="COMBINATORIAL THERAPEUTICS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_17" STRING="complement" FREQUENCY=2 START=1264 END=1274 LEMMA="COMPLEMENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_18" STRING="complement" FREQUENCY=2 START=1552 END=1562 LEMMA="COMPLEMENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_19" STRING="complement activation" FREQUENCY=1 START=1118 END=1139 LEMMA="COMPLEMENT ACTIVATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_20" STRING="complement attack" FREQUENCY=1 START=845 END=862 LEMMA="COMPLEMENT ATTACK" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_21" STRING="conceptual framework" FREQUENCY=1 START=1348 END=1368 LEMMA="CONCEPTUAL FRAMEWORK" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_22" STRING="fluid-phase complement regulators" FREQUENCY=1 START=793 END=826 LEMMA="FLUID-PHASE COMPLEMENT REGULATOR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_23" STRING="gaining momentum" FREQUENCY=1 START=116 END=132 LEMMA="GAINING MOMENTUM" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_24" STRING="host membrane-bound" FREQUENCY=1 START=769 END=788 LEMMA="HOST MEMBRANE-BOUND" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_25" STRING="humoral" FREQUENCY=1 START=547 END=554 LEMMA="HUMORAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_26" STRING="immunosuppressive microenvironment" FREQUENCY=1 START=880 END=914 LEMMA="IMMUNOSUPPRESSIVE MICROENVIRONMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_27" STRING="immunosuppressive microenvironment for tumor growth" FREQUENCY=1 START=880 END=931 LEMMA="TUMOR GROWTH IMMUNOSUPPRESSIVE MICROENVIRONMENT" LEMMA_FREQUENCY=1 HEAD_TERM="immunosuppressive microenvironment" HEAD_LEMMA="IMMUNOSUPPRESSIVE MICROENVIRONMENT"
TERM ID="NYU_TERM_28" STRING="membrane complement regulators" FREQUENCY=1 START=943 END=973 LEMMA="MEMBRANE COMPLEMENT REGULATOR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_29" STRING="novel immunomodulatory role" FREQUENCY=1 START=1233 END=1260 LEMMA="NOVEL IMMUNOMODULATORY ROLE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_30" STRING="novel immunomodulatory role of complement" FREQUENCY=1 START=1233 END=1274 LEMMA="COMPLEMENT NOVEL IMMUNOMODULATORY ROLE" LEMMA_FREQUENCY=1 HEAD_TERM="novel immunomodulatory role" HEAD_LEMMA="NOVEL IMMUNOMODULATORY ROLE"
TERM ID="NYU_TERM_31" STRING="receiving approval" FREQUENCY=1 START=221 END=239 LEMMA="RECEIVING APPROVAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_32" STRING="receiving approval for clinical trials" FREQUENCY=1 START=221 END=259 LEMMA="CLINICAL TRIAL RECEIVING APPROVAL" LEMMA_FREQUENCY=1 HEAD_TERM="receiving approval" HEAD_LEMMA="RECEIVING APPROVAL"
TERM ID="NYU_TERM_33" STRING="therapeutic anti-tumor antibodies" FREQUENCY=1 START=178 END=211 LEMMA="THERAPEUTIC ANTI-TUMOR ANTIBODY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_34" STRING="therapeutic efficacy" FREQUENCY=1 START=367 END=387 LEMMA="THERAPEUTIC EFFICACY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_35" STRING="therapeutic platform" FREQUENCY=1 START=499 END=519 LEMMA="THERAPEUTIC PLATFORM" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_36" STRING="tumor cytotoxicity" FREQUENCY=1 START=696 END=714 LEMMA="TUMOR CYTOTOXICITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_37" STRING="tumor growth" FREQUENCY=2 START=919 END=931 LEMMA="TUMOR GROWTH" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_38" STRING="tumor growth" FREQUENCY=2 START=1159 END=1171 LEMMA="TUMOR GROWTH" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_39" STRING="tumor microenvironment" FREQUENCY=1 START=1282 END=1304 LEMMA="TUMOR MICROENVIRONMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_40" STRING="urging need" FREQUENCY=1 START=481 END=492 LEMMA="URGING NEED" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_41" STRING="urging need for a therapeutic platform" FREQUENCY=1 START=481 END=519 LEMMA="THERAPEUTIC PLATFORM URGING NEED" LEMMA_FREQUENCY=1 HEAD_TERM="urging need" HEAD_LEMMA="URGING NEED"
